One of biotech’s most respected entrepreneurs is betting the novel coronavirus won’t be the last deadly outbreak in his lifetime — and that vaccines won’t be enough to stop a future pandemic from bringing the world to a halt once more.
Tillman Gerngross, the Dartmouth bioengineering professor behind the biotech company Adimab, has founded a new firm dedicated to making antibodies that could protect against the novel coronavirus, called SARS-CoV-2, in addition to any future coronaviruses that might make the leap from animals to humans.
About the Author Reprints
Today, front page story in the San Francisco Chronicle describes researchers finding that antibodies of Covid 19 fade away soner than expected, making a case for symptom treatment therapies.